Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy

Jayatilleke, Irandi; Doolan, Alessandra; Ingles, Jodie; McGuire, Mark A.; Booth, Virginia; Richmond, David; Semsarian, Christopher

doi:10.1016/j.amjcard.2004.01.057

Cited by 74 publications

(43 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence assembled over the last 10 years substantiates that appropriate ICD interventions occur not uncommonly in HCM and are highly effective in terminating potentially lethal ventricular tachyarrhythmias 3,[7][8][9]22,35,36 (Figure 3). Indeed, ICDs have created a new strategy within the HCM armamentarium, and represent the most reliable treatment available for SD prevention.…”

Section: Icd Experience In Hcmmentioning

confidence: 99%

“…9,[81][82][83] Although ICD components have proved generally safe and effective, device-related complications, including infection, pocket hematoma, pneumothorax, and venous thrombosis, are well documented. [7][8][9]35,36,[81][82][83][84] More frequently, Ϸ25% of HCM patients 8 experience inappropriate shocks (5.3%/y) 83 resulting from lead fracture or dislodgement, oversensing, double counting, and programming malfunctions, or triggered inadvertently by sinus tachycardia or atrial fibrillation (although reports of multiple shock "storms" are rare). 7,8,83 Such complications occur most commonly in younger patients, primarily because their activity level and body growth place continual strain on leads, considered the weakest link in this system.…”

Section: Other Considerations Affecting Icds Complicationsmentioning

confidence: 99%

See 1 more Smart Citation

Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

2010

View full text Add to dashboard Cite

Section: Icd Experience In Hcmmentioning

confidence: 99%

Section: Other Considerations Affecting Icds Complicationsmentioning

confidence: 99%

Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

2010

View full text Add to dashboard Cite

“…Hence, the summary estimate of clinical data and outcome is based on 16 studies. 4,7,9,[12][13][14]16,[18][19][20][24][25][26][27][28]30 Thirteen (81%) studies reported on a population of patients with HCM with an ICD for primary or secondary prevention of SCD, 1 (8%) study focused on patients with HCM with an ICD for primary prevention of SCD, and 2 (13%) studies reported on patients with hypertrophic obstructive cardiomyopathy who underwent alcohol septal ablation and had received an ICD.…”

Section: Search Resultsmentioning

confidence: 99%

Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy

Schinkel

Vriesendorp

Sijbrands

et al. 2012

Circ: Heart Failure

150

125

View full text Add to dashboard Cite

P atients with hypertrophic cardiomyopathy (HCM) are at increased risk for sudden cardiac death (SCD), mostly caused by ventricular arrhythmias. SCD may occur as the initial presentation of HCM, often in asymptomatic or mildly symptomatic patients. 1 In fact, HCM is the most frequent cause of SCD in young people, including trained athletes. 2,3 Implantable cardioverter defibrillator (ICD) therapy may effectively terminate potentially life-threatening ventricular arrhythmias, thereby preventing SCD and prolonging life. Still, ICD therapy is not without risk, because inappropriate interventions and device-related complications may occur. Clinical Perspective on p 559Previous observational studies have reported on the use of ICD therapy for primary and secondary preventions of SCD in HCM. A complete overview of outcome and complications after ICD therapy in patients with HCM at risk for SCD is currently not available. The goal of this analysis was to pool the individual studies in an effort to examine the precise rate of cardiac and noncardiac mortality, appropriate and inappropriate interventions, and complications. This knowledge may aid clinical decision making and counseling in patients with HCM at increased risk for SCD considered for ICD therapy. Methods Study DesignThis systematic review and meta-analysis included all available original studies reporting clinical outcome and complications in patients with HCM who underwent ICD implantation. Studies that did not provide data on outcome or complications and review manuscripts were excluded. Studies focussing on SCD in patients with HCM without ICD were excluded. Literature SearchThe online MEDLINE database was searched for literature in Background-Previous observational studies demonstrated that patients with hypertrophic cardiomyopathy at risk for sudden cardiac death (SCD) may benefit from implantable cardioverter defibrillator (ICD) therapy. A complete overview of outcome and complications after ICD therapy is currently not available. This study pools data from published studies on outcome and complications after ICD therapy in patients with hypertrophic cardiomyopathy. Methods and Results-A PubMed database search returned 27 studies on 16 cohorts reporting outcome and complications after ICD therapy in patients with hypertrophic cardiomyopathy. In case of >1 publications on a particular cohort, the publication with the largest number of patients was included in the meta-analysis. ICD interventions, complications, and mortality rates were extracted, pooled, and analyzed. There were 2190 patients (mean age, 42 years; 38% women), most of whom (83%) received an ICD for primary prevention of SCD. Risk factors for SCD were left ventricular wall thickness ≥30 mm (20%), family history of SCD (43%), nonsustained ventricular tachycardia (46%), syncope (41%), and abnormal blood pressure response (25%). During the 3.7-year follow-up, the annualized cardiac mortality rate was 0.6%, the noncardiac mortality rate was 0.4%, and the appropriate ICD intervention rate was 3...

show abstract

“…decade, implantable cardioverter-defibrillators (ICDs) have been effective in the primary prevention of sudden death in HCM, 7,[10][11][12] underscoring the importance of more precise identification of those patients at highest risk.…”

mentioning

confidence: 99%

Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

et al. 2014

View full text Add to dashboard Cite

M ore than 50 years after its contemporary description, hypertrophic cardiomyopathy (HCM) remains the most common cause of sudden death in the young. [1][2][3][4][5][6] Although several clinical markers have proved to be useful guides for risk stratification, 3-5,7 current strategies do not identify all HCM patients at risk for sudden death. 3,5,8,9 Over the last Background-Hypertrophic cardiomyopathy (HCM) is the most common cause of sudden death in the young, although not all patients eligible for sudden death prevention with an implantable cardioverter-defibrillator are identified. Contrast-enhanced cardiovascular magnetic resonance with late gadolinium enhancement (LGE) has emerged as an in vivo marker of myocardial fibrosis, although its role in stratifying sudden death risk in subgroups of HCM patients remains incompletely understood. Methods and Results-We assessed the relation between LGE and cardiovascular outcomes in 1293 HCM patients referred for cardiovascular magnetic resonance and followed up for a median of 3.3 years. Sudden cardiac death (SCD) events (including appropriate defibrillator interventions) occurred in 37 patients (3%

show abstract

Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy

Cited by 74 publications

References 10 publications

Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

Contemporary Insights and Strategies for Risk Stratification and Prevention of Sudden Death in Hypertrophic Cardiomyopathy

Outcome and Complications After Implantable Cardioverter Defibrillator Therapy in Hypertrophic Cardiomyopathy

Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy

Contact Info

Product

Resources

About